In the treatment of patients with newly diagnosed multiple myeloma (MM) who are not eligible for stem cell transplant or are transplant-deferred, adding subcutaneous ...
The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the treatment of ...
Intravenous drip ADT plus cabazitaxel/carboplatin and abiraterone was generally safe, and 78% of patients were progression-free at 1 year, according to findings from ...
RIO DE JANEIRO — Adding isatuximab, or Isa (Sarclisa, Sanofi-Aventis), to bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of patients with newly diagnosed, transplant-ineligible ...
Carfilzomib-based quadruplet regimens are producing deep responses and high MRD negativity in NDMM, challenging bortezomib-based standards. KRd regimens show strong activity in both ...
Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth ...
The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), ...
Daratumumab plus a standard triplet improved minimal residual disease negativity rates in patients with transplant-ineligible multiple myeloma. The quadruplet also improved rates of complete response ...
Early results of a multicenter phase 2 trial exploring the efficacy of daratumumab, pomalidomide, dexamethasone, and ixazomib treatment suggest the regimen is safe and effective in relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results